Amneal Pharmaceuticals, Inc. Class A (AMRX)

NASDAQ:
AMRX
| Latest update: Apr 15, 2026, 5:09 PM

Stock events for Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals' stock has trended upwards by 25.78% in the past six months. In February 2026, Amneal reported its Fourth Quarter and Full Year 2025 financial results, with all three business segments achieving double-digit revenue growth. In January 2026, Amneal Pharmaceuticals was added to the S&P SmallCap 600® Index. In March 2026, a co-founder exercised options and sold approximately $4.8 million worth of stock. In April 2026, the company announced the launch of Bimatoprost Ophthalmic Solution, 0.01%, and analysts have increased price targets for AMRX.

Demand Seasonality affecting Amneal Pharmaceuticals, Inc.’s stock price

Demand for Amneal's pharmaceutical products can exhibit seasonality, influenced by factors such as disease incidence and weather conditions. Demand for cold and flu medications typically rises in winter, while hay fever medication demand increases in spring. The company's diverse portfolio likely experiences some demand fluctuation based on general industry trends.

Overview of Amneal Pharmaceuticals, Inc.’s business

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, and distributes essential medicines, operating in the Healthcare sector within the Drug Manufacturers - Other and Pharmaceutical Products industries. The company is segmented into Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment includes generics, injectables, and biosimilars across various therapeutic areas. The Specialty segment focuses on branded products for central nervous system and endocrine disorders, and Amneal is developing GLP-1 therapies. The AvKARE segment distributes pharmaceuticals to U.S. federal government agencies.

AMRX’s Geographic footprint

Amneal Pharmaceuticals has a global presence with operations in the U.S., India, and Ireland, including manufacturing plants and R&D centers. It has manufacturing facilities in New Jersey, New York, and Kentucky in the U.S., and in Ahmedabad, Dahej, Vizag, and Hyderabad in India. The company also has a commercial office in Mumbai, India, and facilities in Ireland focused on complex delivery formats. Amneal has been expanding its reach with product approvals and collaborations in China and a presence in Europe and Canada.

AMRX Corporate Image Assessment

Amneal Pharmaceuticals' reputation has faced challenges due to regulatory issues. In August 2025, the FDA issued a warning letter citing manufacturing standard violations at its Gujarat, India, facility due to contaminated IV bags. In April 2026, the FDA's OPDP accused Amneal of producing "false and misleading" drug promotions for its biosimilar Alymsys.

Ownership

As of December 2025, institutional investors held 47.9% of outstanding shares, with major holders including Vanguard Group Inc and BlackRock, Inc. Tushar Bhikhubhai Patel is the largest individual shareholder, owning 49.50% of the company. Other notable individual/insider owners include Gautam Patel, Dipan Patel, Chintu Patel, and Chirag K. Patel.

Price Chart

$13.03

0.66%
(1 month)

Top Shareholders

The Vanguard Group, Inc.
5.70%
BlackRock, Inc.
4.55%
Rubric Capital Management LP
3.92%
TPG, Inc.
3.92%
GFH HFEVA LLC
1.95%
Dimensional Holdings, Inc.
1.78%
Morgan Stanley
1.53%
State Street Corp.
1.31%

Trade Ideas for AMRX

Today

Sentiment for AMRX

News
Social

Buzz Talk for AMRX

Today

Social Media

FAQ

What is the current stock price of Amneal Pharmaceuticals, Inc.?

As of the latest update, Amneal Pharmaceuticals, Inc.'s stock is trading at $13.03 per share.

What’s happening with Amneal Pharmaceuticals, Inc. stock today?

Today, Amneal Pharmaceuticals, Inc. stock is down by -0.66%, possibly due to news.

What is the market sentiment around Amneal Pharmaceuticals, Inc. stock?

Current sentiment around Amneal Pharmaceuticals, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Amneal Pharmaceuticals, Inc.'s stock price growing?

Over the past month, Amneal Pharmaceuticals, Inc.'s stock price has decreased by -0.66%.

How can I buy Amneal Pharmaceuticals, Inc. stock?

You can buy Amneal Pharmaceuticals, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol AMRX

Who are the major shareholders of Amneal Pharmaceuticals, Inc. stock?

Major shareholders of Amneal Pharmaceuticals, Inc. include institutions such as The Vanguard Group, Inc. (5.70%), BlackRock, Inc. (4.55%), Rubric Capital Management LP (3.92%) ... , according to the latest filings.